Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alosetron.

H Mucke1, P Cole, X Rabasseda

  • 1Medical Information Department, Prous Science, Barcelona, Spain.

Drugs of Today (Barcelona, Spain : 1998)
|July 9, 2003
PubMed
Summary
This summary is machine-generated.

Alosetron effectively treats diarrhea-predominant irritable bowel syndrome in women by reducing pain and spasms. This 5-HT3 antagonist offers a new option for managing IBS symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The central part of the cyanelle rDNA unit of Cyanophora paradoxa: Sequence comparison with chloroplasts and cyanobacteria.

Plant molecular biology·2013
Same author

Comparison of the cyanelle DNA from two different strains of Cyanophora paradoxa.

Current genetics·2013
Same author

The role of imatinib in the treatment of pulmonary hypertension.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

The management of small sealed sources.

Journal of radiological protection : official journal of the Society for Radiological Protection·2011
Same author

Paraquat and Parkinson's disease: an overview of the epidemiology and a review of two recent studies.

Regulatory toxicology and pharmacology : RTP·2011
Same author

Measurement of the B0 production cross section in pp collisions at sqrt[s] = 7 TeV.

Physical review letters·2011
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Irritable bowel syndrome (IBS) is a common gastrointestinal disorder.
  • Diarrhea-predominant IBS (IBS-D) significantly impacts quality of life, especially in women.
  • Limited therapeutic options exist for managing IBS-D symptoms effectively.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of alosetron, a 5-HT3 receptor antagonist, for treating IBS-D.
  • To compare alosetron's effects against placebo and mebeverine, a smooth muscle relaxant.

Main Methods:

  • Clinical trial involving female patients with IBS-D.
  • Oral administration of alosetron in tablet form.
  • Assessment of symptom improvement, including visceral pain, spasms, and diarrhea over 3 months.

Related Experiment Videos

Main Results:

  • Alosetron demonstrated oral bioavailability and good tolerability.
  • Significant improvement in visceral pain, spasms, and diarrhea compared to placebo and mebeverine in women.
  • No statistically significant symptom alleviation observed in male participants.

Conclusions:

  • Alosetron is an effective treatment for diarrhea-predominant IBS in women.
  • The drug offers significant symptom relief for visceral pain, spasms, and diarrhea.
  • Further research may be needed to explore efficacy in male IBS patients.